A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15; 61(9):1168-78.
-
Adult
-
Adult
-
Antibodies, Anti-Idiotypic
-
Antibodies, Anti-Idiotypic
-
Antibodies, Antinuclear
-
Antibodies, Antinuclear
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Humanized
-
DNA
-
DNA
-
Dose-Response Relationship, Drug
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Double-Blind Method
-
Endpoint Determination
-
Endpoint Determination
-
Female
-
Female
-
Humans
-
Humans
-
Lupus Erythematosus, Systemic
-
Lupus Erythematosus, Systemic
-
Male
-
Male
-
Middle Aged
-
Middle Aged
-
Severity of Illness Index
-
Severity of Illness Index
-
Treatment Outcome
-
Treatment Outcome